Analysis of Factors Influencing Overall Survival of MDS Patients Transplanted with HSCs.
10.19746/j.cnki.issn.1009-2137.2020.04.034
- Author:
Yu-Xin JIANG
1
;
Ling ZHANG
1
;
Zi-Xing CHEN
1
;
Jian-Nong CEN
1
;
Su-Ning CHEN
1
;
Xiao-Fei QI
1
;
Qiao-Cheng QIU
1
;
Yuan-Yuan WANG
2
Author Information
1. The First Affiliated Hospital of Soochow University Jiangsu Institute of Hematology,Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Collaborative Innovation Center of Hematology, Suzhou 215006 ,Jiangsu Province, China.
2. The First Affiliated Hospital of Soochow University Jiangsu Institute of Hematology,Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Collaborative Innovation Center of Hematology, Suzhou 215006 ,Jiangsu Province, China,E-mail: yywang2006@163.com.
- Publication Type:Journal Article
- MeSH:
Adolescent;
Adult;
Aged;
Child;
Child, Preschool;
Hematopoietic Stem Cell Transplantation;
Hematopoietic Stem Cells;
Humans;
Infant;
Infant, Newborn;
Middle Aged;
Myelodysplastic Syndromes;
Prognosis;
Retrospective Studies;
Siblings;
Survival Analysis;
Young Adult
- From:
Journal of Experimental Hematology
2020;28(4):1283-1291
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To analyze the effect of clinical features, routine laboratory examination and related gene mutation on the OS of patients with myelodysplastic syndrome (MDS) after hematopoietic stem cell transplantation (HSCT).
METHODS:121 patients diagnosed as MDS and underwent hematopoietic stem cell transplantation in the First Affiliated Hospital of Soochow University from October 2013 to August 2018 were selected. Basic information of the patients was collected, and blood cells, bone marrow blasts at initial diagnosis, chromosomal karyotypes and gene mutations of the patients were detected.The effect of different factors on overall survival (OS) was analyzed by statistical method.
RESULTS:Kaplan-Meier univariate analysis shows that OS was significanly different among different age groups. The 3-year OS rate of patients aged 0-29 years was (83.3±7.7) %, the 3-year OS rate in patients aged 30-49 years was (58.1±7.7 %), and the 3-year OS rate of patients aged 50-69 years was (31.0±22.6) %, which was statistically different (P＜0.05) between different groups. There were also significant differences in OS among patients with different transplantation types. 3-year OS rate: HLA-matched sibling HSCT＞unrelated HLA-matched HSCT＞haploidentical HSCT＞micro HSCT. The OS rate of patients with bone marrow blasts≥10% seems lower than blasts＜10%, but there was no statistical difference.The 3-year OS rate of patients with chromosomal karyotype complex abnormality was (47.7±11.5) %, and that of patients without complex abnormality was (80±4.2) % which was statistical difference (P＜0.05). Patients with DNMT3A, NRAS, TP53 and GATA2 mutations had shorter OS time compared with patients without mutation of these genes, which shows statistically significant (P＜0.05). COX multivariate analysis showed that age, chromosome karyotype, DNMT3A, TET2, GATA2 and NRAS were the independent factors influencing OS of patients after HSCT, with statistically significant difference.
CONCLUSION:age of patients, donor selection of HSCT, chromosome karyotype, DNMT3A, NRAS, TP53, GATA2 and TET2 gene mutations are all independent factors affecting the OS of patients after HSCT. Therefore, the assessment of the OS of MDS patients with transplantation requires comprehensive consideration.
